142 related articles for article (PubMed ID: 37381796)
21. Head-to-head comparisons of [
Ke ZB; Chen SM; Chen JY; Chen SH; You Q; Sun JB; Xue YT; Sun XL; Wu XH; Zheng QS; Wei Y; Xue XY; Xu N
Eur J Nucl Med Mol Imaging; 2023 Mar; 50(4):1240-1251. PubMed ID: 36416906
[TBL] [Abstract][Full Text] [Related]
22. Establishment and prospective validation of an SUV
Jiao J; Kang F; Zhang J; Quan Z; Wen W; Zhao X; Ma S; Wu P; Yang F; Guo W; Yang X; Yuan J; Shi Y; Wang J; Qin W
Theranostics; 2021; 11(17):8396-8411. PubMed ID: 34373749
[No Abstract] [Full Text] [Related]
23. Findings in 1,123 Men with Preoperative
Raveenthiran S; Yaxley WJ; Franklin T; Coughlin G; Roberts M; Gianduzzo T; Kua B; Samaratunga H; Delahunt B; Egevad L; Wong D; McEwan L; Brown N; Parkinson R; Esler R; Yaxley JW
J Urol; 2022 Mar; 207(3):573-580. PubMed ID: 34694140
[TBL] [Abstract][Full Text] [Related]
24. Correlations of
Topuz ÖV; Aksu A; Erinç SR; Tamam MÖ
Hell J Nucl Med; 2021; 24(1):60-65. PubMed ID: 33866340
[TBL] [Abstract][Full Text] [Related]
25. Retrospective correlation of
Onal C; Torun N; Oymak E; Guler OC; Reyhan M; Yapar AF
Ann Nucl Med; 2020 Jun; 34(6):388-396. PubMed ID: 32221791
[TBL] [Abstract][Full Text] [Related]
26.
von Eyben FE; Picchio M; von Eyben R; Rhee H; Bauman G
Eur Urol Focus; 2018 Sep; 4(5):686-693. PubMed ID: 28753806
[TBL] [Abstract][Full Text] [Related]
27. Gallium-68-prostate-specific membrane antigen (
van Leeuwen PJ; Donswijk M; Nandurkar R; Stricker P; Ho B; Heijmink S; Wit EMK; Tillier C; van Muilenkom E; Nguyen Q; van der Poel HG; Emmett L
BJU Int; 2019 Jul; 124(1):62-68. PubMed ID: 30074667
[TBL] [Abstract][Full Text] [Related]
28. A single-center, multi-factor, retrospective study to improve the diagnostic accuracy of primary prostate cancer using [
Lv J; Yu H; Yin H; Shi Y; Shi H
Eur J Nucl Med Mol Imaging; 2024 Feb; 51(3):919-927. PubMed ID: 37940684
[TBL] [Abstract][Full Text] [Related]
29. Can SUVmax values of Ga-68-PSMA PET/CT scan predict the clinically significant prostate cancer?
Demirci E; Kabasakal L; Şahin OE; Akgün E; Gültekin MH; Doğanca T; Tuna MB; Öbek C; Kiliç M; Esen T; Kural AR
Nucl Med Commun; 2019 Jan; 40(1):86-91. PubMed ID: 30395048
[TBL] [Abstract][Full Text] [Related]
30. Incremental Impact of [
Szigeti F; Schweighofer-Zwink G; Meissnitzer M; Hauser-Kronberger C; Hitzl W; Kunit T; Forstner R; Pirich C; Beheshti M
Mol Imaging Biol; 2022 Feb; 24(1):50-59. PubMed ID: 34519966
[TBL] [Abstract][Full Text] [Related]
31. Diverse PSMA expression in primary prostate cancer: reason for negative [
Cytawa W; Kircher S; Kübler H; Werner RA; Weber S; Hartrampf P; Bandurski T; Lass P; Połom W; Matuszewski M; Wester HJ; Lapa C; Rosenwald A; Seitz AK; Buck AK
Eur J Nucl Med Mol Imaging; 2022 Sep; 49(11):3938-3949. PubMed ID: 35556160
[TBL] [Abstract][Full Text] [Related]
32. Assessing the accuracy of
Paterson F; Nottage M; Kitchener M; Jarvis M; Reid J; Oakden-Rayner L
J Med Imaging Radiat Oncol; 2022 Apr; 66(3):319-323. PubMed ID: 34250746
[TBL] [Abstract][Full Text] [Related]
33. Detection Efficacy of Hybrid
Einspieler I; Rauscher I; Düwel C; Krönke M; Rischpler C; Habl G; Dewes S; Ott A; Wester HJ; Schwaiger M; Maurer T; Eiber M
J Nucl Med; 2017 Jul; 58(7):1081-1087. PubMed ID: 28209912
[TBL] [Abstract][Full Text] [Related]
34. Detection level and pattern of positive lesions using PSMA PET/CT for staging prior to radiation therapy.
Schmidt-Hegemann NS; Fendler WP; Buchner A; Stief C; Rogowski P; Niyazi M; Eze C; Li M; Bartenstein P; Belka C; Ganswindt U
Radiat Oncol; 2017 Nov; 12(1):176. PubMed ID: 29126446
[TBL] [Abstract][Full Text] [Related]
35.
Sathekge M; Lengana T; Maes A; Vorster M; Zeevaart J; Lawal I; Ebenhan T; Van de Wiele C
Eur J Nucl Med Mol Imaging; 2018 Feb; 45(2):226-234. PubMed ID: 29101444
[TBL] [Abstract][Full Text] [Related]
36. PSA-stratified detection rates for [
Derlin T; Schmuck S; Juhl C; Zörgiebel J; Schneefeld SM; Walte ACA; Hueper K; von Klot CA; Henkenberens C; Christiansen H; Thackeray JT; Ross TL; Bengel FM
Eur J Nucl Med Mol Imaging; 2018 Jun; 45(6):913-922. PubMed ID: 29308527
[TBL] [Abstract][Full Text] [Related]
37. The role of 68Ga-PSMA-I&T PET/CT in the pretreatment staging of primary prostate cancer.
Meyrick DP; Asokendaran M; Skelly LA; Lenzo NP; Henderson A
Nucl Med Commun; 2017 Nov; 38(11):956-963. PubMed ID: 28922335
[TBL] [Abstract][Full Text] [Related]
38. Assessment of Prostate Carcinoma Aggressiveness: Relation to
Ferda J; Hes O; Hora M; Ferdová E; Pernický J; Rudnev V; Pecen L; Topolčan O; Mírka H
Anticancer Res; 2023 Jan; 43(1):449-453. PubMed ID: 36585198
[TBL] [Abstract][Full Text] [Related]
39. Biodistribution of [(68)Ga]PSMA-HBED-CC in Patients with Prostate Cancer: Characterization of Uptake in Normal Organs and Tumour Lesions.
Prasad V; Steffen IG; Diederichs G; Makowski MR; Wust P; Brenner W
Mol Imaging Biol; 2016 Jun; 18(3):428-36. PubMed ID: 27038316
[TBL] [Abstract][Full Text] [Related]
40. Clinicopathological predictors of positive
Aydin AM; Haberal B; Artykov M; Bilen CY; Yazici S
Ann Nucl Med; 2019 May; 33(5):326-332. PubMed ID: 30778860
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]